Form D · Pharmaceuticals
Mereo Biopharma Group plc
London, X0 · CIK 0001719714
Offering snapshot reported Jun 12, 2020 · SEC filing
- Reported sold
- $70M Offering amount: $70M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Jun 3, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2020 | Initial | $70,000,000 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $4.2M
- Finders' fees
- $0
- Form D file number
- 021-368827
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| SVB Leerink LLC | 39011 |
Source: Form D, filed Jun 12, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Bains | Director |
| Paul Blackburn | Director |
| Dr. Anders Ekblom | Director |
| Dr. Peter Fellner | Director |
| Jill Henrich | Executive |
| Richard Jones | Director, Executive |
| Kunal Kashyap | Director |
| Dr. Alastair Mac Kinnon | Executive |
| Dr. Deepa Pakianathan | Director |
| John Richard | Executive |
| Dr. Denise Scots Knight | Director, Executive |
| Charles Sermon | Executive |
| Michael Wyzga | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1 Cavendish Place
London, X0, W1G 0QF
London, X0, W1G 0QF